Catabasis’s Future In Doubt After DMD Phase III Failure
Another failed study in Duchenne muscular dystrophy spells the end for edasalonexent and possibly the firm.
You may also be interested in...
Scrip caught up with Olema CEO Sean Bohen ahead of a crucial combination data readout due this month for its novel SERD, palazestrant, which it hopes will put the drug on the path to a $10bn-plus breast cancer market.
A sea of troubles continues for the German conglomerate as a Phase III failure for one of its future blockbuster hopes sends shares diving. Flickers of hope remain for the product in stroke.
The future for AstraZeneca/Daiichi Sankyo’s TROP2-targeted ADC candidate Dato-DXd is looking more positive after details of their TROPION-Lung01 and TROPION-Breast01 Phase III studies were presented at ESMO.